WHO issues guidance on safe implementation of AI in medicine

23 October 2023
who_flag_big

As drugmakers around the world  rush to embrace the potential of artificial intelligence (AI) in the design and development of new medications, the World Health Organization has urged caution.

A new  publication from the WHO outlines key regulatory considerations, emphasizing the importance of establishing “safety and effectiveness.”

The global health body has argued in favor of making appropriate systems rapidly available in order to boost access to medicines, and encouraging dialogue between developers, regulators, manufacturers, health workers, and patients to ensure the best outcomes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology